Veröffentlichungsdatum: 10 Mai 2019
Projektträger – zwischengeschaltetes Finanzinstitut
BIAL PORTELA & CA SA
The project concerns BIAL's research, development and innovation (RDI) investments for the 2018-2021 period.
The promoter's research and development (R&D) investment programme has the objective to discover, develop and provide therapeutic solutions in various therapeutic areas such as epilepsy, pulmonary arterial hypertension and glaucoma.
- Industrie - Verarbeitendes Gewerbe/Herstellung von Waren
Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)
EUR 60 million
Gesamtkosten (voraussichtlicher Betrag)
EUR 105 million
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under the Directive 2014/52/EU amending the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
The promoter has been assessed by the EIB as being a private company not being subject to EU rules on public procurement or concessions. However, if after the project appraisal, the EIB were to conclude that the promoter is after all subject to EU public procurement legislation: Directive 2014/23/EU / 2014/24/EU / 2014/25/EU, where applicable, then the Bank would require the promoter to ensure that contracts for the implementation of the project will be tendered in accordance with the relevant applicable EU procurement legislation: Directive 2014/23/EU / 2014/24/EU / 2014/25/EU, where applicable, as well as Directive 92/13/EEC or Directive 89/665/EEC as interpreted by the Court of Justice of the EU, with the publication of tender notices in the Official Journal of the EU, as and where required.
In Prüfung - 14/11/2018
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).